Inagaki Hiroshi, Nakamura Tsuneya, Li Chunmei, Sugiyama Toshiro, Asaka Masahiro, Kodaira Jyunichi, Iwano Masahiro, Chiba Tsutomu, Okazaki Kazuichi, Kato Atsunaga, Ueda Ryuzo, Eimoto Tadaaki, Okamoto Shiro, Sasaki Naomi, Uemura Naomi, Akamatsu Taiji, Miyabayashi Hideharu, Kawamura Yoko, Goto Hidemi, Niwa Yasumasa, Yokoi Takio, Seto Masao, Nakamura Shigeo
Department of Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Am J Surg Pathol. 2004 Dec;28(12):1560-7. doi: 10.1097/00000478-200412000-00003.
Gastric MALT lymphoma shows unique features including regression by Helicobacter pylori eradication and API2-MALT1 fusion. We performed a molecular and clinicopathologic study for 115 cases. All eradication-responsive cases were devoid of API2-MALT1 fusion. All tumors positive for the fusion and all negative for H. pylori infection were nonresponsive to the eradication. Consequently, gastric MALT lymphomas were divided into three groups: Eradication-responsive and fusion-negative (group A, n = 72), eradication-nonresponsive and fusion-negative (group B, n = 22), and eradication-nonresponsive and fusion-positive (group C, n = 21). Group A tumors were characterized by low clinical stage and superficial gastric wall involvement, and group C tumors by low H. pylori infection rate, advanced clinical stage, and nuclear BCL10 expression. All group C tumors showed exclusively low-grade histology. Group B tumors, which have not been well recognized, frequently showed nodal involvement, deep gastric wall involvement, and advanced clinical stage, and sometimes an increased large cell component. A multivariate discriminant analysis revealed that responsiveness to the eradication could be predicted accurately by negative API2-MALT1 fusion, positive H. pylori infection, low clinical stage, and superficial gastric wall invasion, the former being the most important factor for the prediction. This 3-group categorization may be helpful for a comprehensive understanding of gastric MALT lymphoma.
胃黏膜相关淋巴组织淋巴瘤具有独特特征,包括幽门螺杆菌根除后肿瘤消退以及API2-MALT1融合。我们对115例病例进行了分子及临床病理研究。所有对根除治疗有反应的病例均无API2-MALT1融合。所有融合阳性且幽门螺杆菌感染阴性的肿瘤对根除治疗无反应。因此,胃黏膜相关淋巴组织淋巴瘤分为三组:根除治疗有反应且融合阴性(A组,n = 72)、根除治疗无反应且融合阴性(B组,n = 22)、根除治疗无反应且融合阳性(C组,n = 21)。A组肿瘤的特点是临床分期低和胃壁浅层受累,C组肿瘤的特点是幽门螺杆菌感染率低、临床分期晚和核BCL10表达。所有C组肿瘤均仅表现为低级别组织学。尚未得到充分认识的B组肿瘤常表现为淋巴结受累、胃壁深层受累和临床分期晚,有时大细胞成分增加。多因素判别分析显示,通过API2-MALT1融合阴性、幽门螺杆菌感染阳性、临床分期低和胃壁浅层浸润可准确预测对根除治疗的反应性,其中前者是预测的最重要因素。这种三分法分类可能有助于全面了解胃黏膜相关淋巴组织淋巴瘤。